Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 7/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | XDH | P47989 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | MGAM | O43451 | 1/20 | 0.42 |
| ▸ | SI | P14410 | 1/20 | 0.42 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30386718 | 1.00 | CASP1 (0.52) | CASP1MAPTRAB9ANPC1MEN1 | |
| SCHEMBL30461132 | 0.89 | MAOB (0.54) | CASP1MAPTRAB9ANPC1MEN1 | |
| SCHEMBL929507 | 0.80 | MAPT (0.63) | MAPTRAB9ANPC1PKMTDP1 | |
| SCHEMBL30914344 | 0.80 | MAPT (0.63) | MAPTRAB9ANPC1PKMTDP1 | |
| SCHEMBL27833835 | 0.74 | ALDH1A1 (0.45) | MAPTRAB9ANPC1MEN1KMT2A | |
| SCHEMBL256008 | 0.74 | HSD11B1 (0.48) | CASP1MAPTRAB9ANPC1MEN1 | |
| SCHEMBL11171259 | 0.73 | MAPT (0.61) | MAPTRAB9ANPC1MEN1KMT2A | |
| SCHEMBL27617094 | 0.72 | RAB9A (0.56) | CASP1MAPTRAB9ANPC1MEN1 | |
| SCHEMBL11624753 | 0.71 | AR (0.45) | RAB9AMEN1KMT2APOLBTDP1 | |
| SCHEMBL28503258 | 0.71 | RAB9A (0.47) | CASP1MAPTRAB9ANPC1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250235453-A1 | TRIAZOLOPYRIDAZINE COMPOUNDS USEFUL AS RAC1 INHIBITORS | REVERE PHARMACEUTICALS | 2025-07-24 | — | — | US | disclosed |
| WO-2023076259-A1 | TRIAZOLOPYRIDAZINE COMPOUNDS USEFUL AS RAC1 INHIBITORS | REVERE PHARMACEUTICALS (US) | 2023-05-04 | — | — | WO | disclosed |
| EP-2316836-A1 | Substituted diazabicycloalkane derivatives as ligands at alpha 7 nicotinic acetylcholine receptors | Abbott Laboratories (US) | 2011-05-04 | — | — | EP | disclosed |
| US-7872010-B2 | Substituted diazabicycloalkane derivatives having affinity for nicotinic acetylcholine receptors | ABBOTT LABORATORIES (US) | 2011-01-18 | — | — | US | disclosed |
| US-20080275048-A1 | Substituted Diazabicycloalkane Derivates | ABBOTT LABORATORIES (US) | 2008-11-06 | — | — | US | disclosed |
| US-7399765-B2 | Substituted diazabicycloalkane derivatives | ABBOTT LABORATORIES (US) | 2008-07-15 | — | — | US | disclosed |
| CN-101189233-A | Substituted diazabicycloalkane derivatives as ligands for the alpha 7 nicotinic acetylcholine receptor | ABBOTT LAB (US) | 2008-05-28 | — | — | CN | disclosed |
| EP-1664045-A1 | SUBSTITUTED DIAZABICYCLOALKANE DERIVATIVES AS LIGANDS AT ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTORS | Abbott Laboratories (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20050101602-A1 | For example, 3-(6-phenyl-pyridazin-3-yl)-3,8-diaza-bicyclo[3.2.1]octane; for treatment or prevention of conditions and disorders related to nAChR activity, and more particularly alpha 7 nAChR activity, such as attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease | ABBVIE INC. | 2005-05-12 | — | — | US | disclosed |
| WO-2005028477-A1 | SUBSTITUTED DIAZABICYCLOALKANE DERIVATIVES AS LIGANDS AT ALPHA 7 NICOTINIC ACETY LCHOLINE RECEPTORS | ABBOTT LABORATORIES (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275048-A1 | Substituted Diazabicycloalkane Derivates | CHRNA7, CHRNA1, CHRNA2 | CASP1 2535/4885MAPT 3323/4885RAB9A 1215/4885 |
| US-20250235453-A1 | TRIAZOLOPYRIDAZINE COMPOUNDS USEFUL AS RAC1 INHIBITORS | RAC1, TNK2, GDI2 | CASP1 4154/4885MAPT 1537/4885RAB9A 63/4885 |
| US-20050101602-A1 | For example, 3-(6-phenyl-pyridazin-3-yl)-3,8-diaza-bicyclo[3.2.1]octane; for treatment or prevention of conditions and disorders related to nAChR activity, and more particularly alpha 7 nAChR activity, such as attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease | CHRNA7, CHRNA2, CHRNA6 | CASP1 2456/4885MAPT 333/4885RAB9A 1951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.